Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review

Bibliography

• Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005;46(4):470-2
   PubMed Web of Science ®Google Scholar
• Vaughn BV, Ali I. Sleep and epilepsy: opportunities for diagnosis and treatment. Neurol Clin 2012;30(4):1249-74
   PubMed Web of Science ®Google Scholar
• Dulla CG, Dobelis P, Pearson T, et al. Adenosine and ATP link PCO2 to cortical excitability via pH. Neuron 2005;48(6):1011-23
   PubMed Web of Science ®Google Scholar
• Foyaca-Sibat H. Novel Aspects on Epilepsy. InTech, Rijeka, Croatia; 2011
   Google Scholar
• Wirrell EC, Camfield PR, Gordon KE, et al. Will a critical level of hyperventilation-induced hypocapnia always induce an absence seizure? Epilepsia 1996;37(5):459-62
   PubMed Web of Science ®Google Scholar
• Jonas J, Vignal J-P, Baumann C, et al. Effect of hyperventilation on seizure activation: potentiation by antiepileptic drug tapering. J Neurol Neurosurg Psychiatr 2011;82(8):928-30
   PubMed Web of Science ®Google Scholar
• Parmet S, Lynm C, Golub RM. JAMA patient page. Epilepsy JAMA 2011;305(16):1722
   Google Scholar
• Woodbury DM, Rollins LT, Gardner MD, et al. Effects of carbon dioxide on brain excitability and electrolytes. Am J Physiol 1958;192(1):79-90
   PubMed Web of Science ®Google Scholar
• Tolner EA, Hochman DW, Hassinen P, et al. Five percent CO2 is a potent, fast-acting inhalation anticonvulsant. Epilepsia 2011;52(1):104-14
   PubMed Web of Science ®Google Scholar
• Yuen AWC, Sander JW. Can slow breathing exercises improve seizure control in people with refractory epilepsy? A hypothesis. Epilepsy Behav 2010;18(4):331-4
   PubMed Web of Science ®Google Scholar
• Messerchmidt A, Bode W, Cygler M. Handbook of Metalloproteins. John Wiley and Sons Ltd, Madison, Wisconsin; 2004
   Google Scholar
• Domsic JF, Avvaru BS, Kim CU, et al. Entrapment of carbon dioxide in the active site of carbonic Anhydrase II. J Biol Chem 2008;283(45):30766-71
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin Ther Patent 2006;16(12):1627-64
   Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23(2):146-89
   PubMed Web of Science ®Google Scholar
• Krishnamurthy VM, Kaufman GK, Urbach AR, et al. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev 2008;108(3):946-1051
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10(10):767-77
   PubMed Web of Science ®Google Scholar
• Chegwidden WR, Carter ND. The carbonic anhydrases: new horizons. Birkhauser; 2000
   Google Scholar
• Aggarwal M, Boone CD, Kondeti B, McKenna R. Structural annotation of human carbonic anhydrases. J Enzyme Inhib Med Chem 2012;28(2):267-77
   PubMed Web of Science ®Google Scholar
• Ulmasov B, Waheed A, Shah GN, et al. Purification and kinetic analysis of recombinant CA XII, a membrane carbonic anhydrase overexpressed in certain cancers. Proc Natl Acad Sci USA 2000;97(26):14212-17
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Conway J. Carbonic anhydrase: its inhibitors and activators. CRC Press; Boca Raton, FL, USA: 2004
   Google Scholar
• Nishimori I, Minakuchi T, Onishi S, et al. Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem 2007;15(23):7229-36
   PubMed Web of Science ®Google Scholar
• Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem 2004;47(5):1272-9
   PubMed Web of Science ®Google Scholar
• Nishimori I, Vullo D, Innocenti A, et al. Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J Med Chem 2005;48(24):7860-6
   PubMed Web of Science ®Google Scholar
• Nishimori I, Minakuchi T, Onishi S, et al. Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. J Med Chem 2007;50(2):381-8
   PubMed Web of Science ®Google Scholar
• Lehtonen J, Shen B, Vihinen M, et al. Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J Biol Chem 2004;279(4):2719-27
   PubMed Web of Science ®Google Scholar
• Supuran CT, Ilies MA, Scozzafava A. Carbonic anhydrase inhibitors — Part 29 1: interaction of isozymes I, II and IV with benzolamide-like derivatives. Eur J Med Chem 1998;33(9):739-51
   Web of Science ®Google Scholar
• Scozzafava A, Briganti F, Ilies MA, et al. Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. J Med Chem 2000;43(2):292-300
   PubMed Web of Science ®Google Scholar
• Winum J-Y, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49(24):7024-31
   PubMed Web of Science ®Google Scholar
• De Simone G, Vitale RM, Di Fiore A, et al. Carbonic anhydrase inhibitors: hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem 2006;49(18):5544-51
   PubMed Web of Science ®Google Scholar
• Maren TH, Conroy CW, Wynns GC, et al. Renal and cerebrospinal fluid formation pharmacology of a high molecular weight carbonic anhydrase inhibitor. J Pharmacol Exp Ther 1997;280(1):98-104
   PubMed Web of Science ®Google Scholar
• Ilies MA, Masereel B, Rolin S, et al. Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity. Bioorg Med Chem 2004;12(10):2717-26
   PubMed Web of Science ®Google Scholar
• Sun M-K, Alkon DL. Carbonic anhydrase gating of attention: memory therapy and enhancement. Trends Pharmacol Sci 2002;23(2):83-9
   PubMed Web of Science ®Google Scholar
• Ruusuvuori E, Li H, Huttu K, et al. Carbonic anhydrase isoform VII acts as a molecular switch in the development of synchronous gamma-frequency firing of hippocampal CA1 pyramidal cells. J Neurosci 2004;24(11):2699-707
   PubMed Web of Science ®Google Scholar
• Ma X, Zhang Y, Yang Z, et al. Childhood absence epilepsy: electroclinical features and diagnostic criteria. Brain Dev 2011;33(2):114-19
   PubMed Web of Science ®Google Scholar
• Brzezinski J, Kjallquist A, Siesjo BK. Mean carbon dioxide tension in the brain after carbonic anhydrase inhibition. J Physiol (Lond.) 1967;188(1):13-23
   Google Scholar
• Gray WD, Rauh CE. The anticonvulsant action of carbon dioxide: interaction with reserpine and inhibitors of carbonic anhydrase. J Pharmacol Exp Ther 1968;163(2):431-8
   PubMed Web of Science ®Google Scholar
• Leniger T, Wiemann M, Bingmann D, et al. Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons. Epilepsia 2002;43(5):469-74
   PubMed Web of Science ®Google Scholar
• Lerche H, Jurkat-Rott K, Lehmann-Horn F. Ion channels and epilepsy. Am J Med Genet 2001;106(2):146-59
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia 2005;46(Suppl 9):140-8
   PubMed Web of Science ®Google Scholar
• Reiss WG, Oles KS. Acetazolamide in the treatment of seizures. Ann Pharmacother 1996;30(5):514-19
   PubMed Web of Science ®Google Scholar
• Inoue H, Hazama H, Hamazoe K, et al. Antipsychotic and prophylactic effects of acetazolamide (Diamox) on atypical psychosis. Folia Psychiatr Neurol Jpn 1984;38(4):425-36
   PubMedGoogle Scholar
• Wolf P. Acute drug administration in epilepsy: a review. CNS Neurosci Ther 2011;17(5):442-8
   PubMed Web of Science ®Google Scholar
• Lim LL, Foldvary N, Mascha E, et al. Acetazolamide in women with catamenial epilepsy. Epilepsia 2001;42(6):746-9
   PubMed Web of Science ®Google Scholar
• Ansell B, Clarke E. Acetazolamide in treatment of epilepsy. Br Med J 1956;1(4968):650-4
   PubMed Web of Science ®Google Scholar
• Lombroso CT, Forxythe I. A long-term follow-up of acetazolamide (diamox) in the treatment of epilepsy. Epilepsia 1960;1:493-500
   PubMed Web of Science ®Google Scholar
• Hoddevik GH. Acetazolamide–are there reasons for its revival in antiepileptic treatment? Tidsskr Nor Laegeforen 2000;120(9):1042-5
   PubMedGoogle Scholar
• Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52(9):1882-7
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Yang LPH. Topiramate: a review of its use in the treatment of epilepsy. Drugs 2007;67(15):2231-56
   PubMed Web of Science ®Google Scholar
• Guerrini R, Carpay J, Groselj J, et al. Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. Seizure 2005;14(6):371-80
   PubMed Web of Science ®Google Scholar
• Arroyo S, Dodson WE, Privitera MD, et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 2005;112(4):214-22
   PubMed Web of Science ®Google Scholar
• Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52(7):1330-7
   PubMed Web of Science ®Google Scholar
• Elterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 1999;52(7):1338-44
   PubMed Web of Science ®Google Scholar
• De Simone G, Scozzafava A, Supuran CT. Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des 2009;74(3):317-21
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Fut Med Chem 2011;3(9):1165-80
   PubMed Web of Science ®Google Scholar
• Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13(5):841-5
   PubMed Web of Science ®Google Scholar
• Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 1997;231(3):123-6
   PubMed Web of Science ®Google Scholar
• DeLorenzo RJ, Sombati S, Coulter DA. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 2000;41(Suppl 1):S40-4
   PubMed Web of Science ®Google Scholar
• Taverna S, Sancini G, Mantegazza M, et al. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther 1999;288(3):960-8
   PubMed Web of Science ®Google Scholar
• McLean MJ, Bukhari AA, Wamil AW. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 2000;41(Suppl 1):S21-4
   PubMed Web of Science ®Google Scholar
• Zhang X, Velumian AA, Jones OT, et al. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000;41(Suppl 1):S52-60
   PubMed Web of Science ®Google Scholar
• Skradski S, White HS. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000;41(Suppl 1):S45-7
   PubMed Web of Science ®Google Scholar
• Loring DW, Williamson DJ, Meador KJ, et al. Topiramate dose effects on cognition: a randomized double-blind study. Neurology 2011;76(2):131-7
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Ben-Menachem E, Chouette I, et al. Zonisamide: its pharmacology, efficacy and safety in clinical trials. Acta Neurol Scand Suppl 2012;(194):19-28
   PubMedGoogle Scholar
• Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987;413(1):185-8
   PubMed Web of Science ®Google Scholar
• Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12(1):21-7
   PubMed Web of Science ®Google Scholar
• Matar N, Jin W, Wrubel H, et al. Zonisamide block of cloned human T-type voltage-gated calcium channels. Epilepsy Res 2009;83(2-3):224-34
   PubMed Web of Science ®Google Scholar
• Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 1996;5(2):115-19
   PubMed Web of Science ®Google Scholar
• Dupont S, Stefan H. Zonisamide in clinical practice. Acta Neurol Scand Suppl 2012;(194):29-35
   PubMedGoogle Scholar
• Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;13(Suppl 1):S5-9; discussion S10
   PubMed Web of Science ®Google Scholar
• Rosler TW, Arias-Carrion O, Hoglinger GU. Zonisamide: aspects in neuroprotection. Exp Neurol 2010;224(2):336-9
   PubMed Web of Science ®Google Scholar
• Gross-Selbeck G. Idiopathic epilepsy with generalized seizures in early childhood. Monatsschr Kinderheilkd 1992;140(8):451-6
   PubMed Web of Science ®Google Scholar
• Doose H, Baier WK, Ernst JP, et al. Benign partial epilepsy–treatment with sulthiame. Dev Med Child Neurol 1988;30(5):683-4
   PubMed Web of Science ®Google Scholar
• Ben-Zeev B, Watemberg N, Lerman P, et al. Sulthiame in childhood epilepsy. Pediatr Int 2004;46(5):521-4
   PubMed Web of Science ®Google Scholar
• Wirrell E, Sherman EMS, Vanmastrigt R, et al. Deterioration in cognitive function in children with benign epilepsy of childhood with central temporal spikes treated with sulthiame. J Child Neurol 2008;23(1):14-21
   PubMed Web of Science ®Google Scholar
• Bastie J, Gallardo-Pons F. Methazolamide trials in the treatment of generalized epilepsy. Gaz Med Fr 1963;70:2594-5
   PubMedGoogle Scholar
• Aggarwal M, McKenna R. Update on carbonic anhydrase inhibitors: a patent review (2008 - 2011). Expert Opin Ther Pat 2012;22(8):903-15
   PubMed Web of Science ®Google Scholar
• Fang Z, Hu D, Zheng B, et al. Method for preparing topiramate. CN101979395; 2011
   Google Scholar
• Wang L-H, Huang C-T. Process for the preparation and purification of topiramate. TW201127842; 2011
   Google Scholar
• Zuo X, Yang Y, Zou X, et al. Method for producing topiramate. CN101450951; 2009
   Google Scholar
• Ru I, Milo I. Procedure for preparation of topiramate. SI22298; 2007
   Google Scholar
• Berkner JE, Duncan S, Mills J. Process for the preparation of anticonvulsant derivatives of topiramate. HK1088336; 2008
   Google Scholar
• Madhav ST, Pramod MK, Irwin SG. Pharmaceutical composition of topiramate. MY125821; 2006
   Google Scholar
• Ehrenberg B. Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological Conditions. WO2010036977; 2010
   Google Scholar
• Edgren D, Jao F, Kimbel R, et al. Novel drug compositions and dosage forms of topiramate. US2007243254; 2007
   Google Scholar
• Cloyd JC. Topiramate compositions and methods for their use. WO2008034040; 2008
   Google Scholar
• Yam N, Shivanand P, Jao F, et al. Novel drug compositions and dosage forms of topiramate. MXPA06007510A; 2009
   Google Scholar
• Ross MSF, Andrearczyk-Frost J, Okularczyk M, et al. Pharmaceutical composition containing topiramate or its pharmaceutically admitted salt and its production method. PL201327; 2009
   Google Scholar
• Cloyd JC. Topiramate Compositions and Methods of Making and Using the Same. US2009239942; 2009
   Google Scholar
• Shapira NA, Lessig MC, Driscoll DJ, et al. Treatments for neurogenetic disorders, impulse control disorders, and wound healing. US2008021094; 2008
   Google Scholar
• Li S, Gao C, Zhong W, et al. Topiramate sustained-release drug composition, method for preparing same and application of Topiramate sustained-release drug composition. CN102579367; 2012
   Google Scholar
• Nghiem T, Jackson G. Controlled release formulations using intelligent polymers. US2013004575; 2013
   Google Scholar
• Liang L, Wang H, Bhatt PP, et al. Sustained-release formulations of topiramate. US2012321708; 2012
   Google Scholar
• Li S, Lam A, Dong L. Controlled release of topirimate in liquid dosage forms. KR20060120193; 2006
   Google Scholar
• Padmanabh PB, Likan L, Hua W. Enhanced immediate release formulations of topiramate. MX2009003911; 2009
   Google Scholar
• Mirza NS, Alfirevic A, Jorgensen A, et al. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics 2011;21(5):297-302
   PubMed Web of Science ®Google Scholar
• Aronne L. Combination therapies for the treatment of obesity. WO2011041632; 2011
   Google Scholar
• Najarian T. Combination therapy for effecting weight loss and treating obesity. US2010105765; 2010
   Google Scholar
• Najarian T, Tam PY, Wilson LF. Escalating dosing regimen for effecting weight loss and treating obesity. US2009304785; 2009
   Google Scholar
• Najarian T, Tam P, Wilson L. Compositions and methods for treating obesity and related disorders. WO2008153632; 2008
   Google Scholar
• Tam PY, Wilson LF. Compositions and methods for treating obesity and related disorders. US2008255093; 2008
   Google Scholar
• Goldsmith IL. Combination therapy for weight loss. US2009054372; 2009
   Google Scholar
• Johnson B, Tiouririne NA-D, Lynch WJ. Medication combinations for the treatment of alcoholism and drug addiction. WO2009029308; 2009
   Google Scholar
• Johnson B, Tiouririne NA-D, Lynch WJ. Topiramate plus naltrexone for the treatment of addictive disorders. US2012302592; 2012
   Google Scholar
• Johnson B, Tiouririne NA-D. combined effects of topiramate and ondansetron on alcohol consumption. CN101663028; 2009
   Google Scholar
• Johnson B, Touririne NA-D. Combined effects of topiramate and ondansetron on alcohol consumption. MX2009006672; 2010
   Google Scholar
• Chesler M. Regulation and modulation of pH in the brain. Physiol Rev 2003;83(4):1183-221
   PubMed Web of Science ®Google Scholar
• Kaila K, Paalasmaa P, Taira T, et al. pH transients due to monosynaptic activation of GABAA receptors in rat hippocampal slices. Neuroreport 1992;3(1):105-8
   PubMed Web of Science ®Google Scholar
• Kida E, Palminiello S, Golabek AA, et al. Carbonic anhydrase II in the developing and adult human brain. J Neuropathol Exp Neurol 2006;65(7):664-74
   PubMed Web of Science ®Google Scholar
• Hussain SA, Ganesan R, Reynolds G, et al. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 2007;96(1):104-9
   PubMed Web of Science ®Google Scholar
• Trastour C, Benizri E, Ettore F, et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007;120(7):1451-8
   PubMed Web of Science ®Google Scholar
• Swinson DEB, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003;21(3):473-82
   PubMed Web of Science ®Google Scholar
• Opavsky R, Pastorekova S, Zelnik V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996;33(3):480-7
   PubMed Web of Science ®Google Scholar
• Hilvo M, Baranauskiene L, Salzano AM, et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 2008;283(41):27799-809
   PubMed Web of Science ®Google Scholar
• Antel J, Wurl M, Waldeck H, et al. Novel sulfamate compounds for medical use. MX2010002869; 2010
   Google Scholar
• Supuran C, Benedini F, Biondi S, et al. Nitrate Esters of carbonic Anhydrase inhibitors. WO2008071421; 2008
   Google Scholar
• Jaime LM. Carbonic Anhydrase inhibitor. MXPA04001268A; 2004
   Google Scholar
• Preston WA, Doyon DJ, Simmons SP. Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form. US5776489; 1998
   Google Scholar
• Turkmen H, Durgun M, Yilmaztekin S, et al. Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX. Bioorg Med Chem Lett 2005;15(2):367-72
   PubMed Web of Science ®Google Scholar
• Maryanoff BE, Costanzo MJ, Nortey SO, et al. Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. J Med Chem 1998;41(8):1315-43
   PubMed Web of Science ®Google Scholar
• Unverferth K, Engel J, Hofgen N, et al. Synthesis, anticonvulsant activity, and structure-activity relationships of sodium channel blocking 3-aminopyrroles. J Med Chem 1998;41(1):63-73
   PubMed Web of Science ®Google Scholar
• Temperini C, Innocenti A, Mastrolorenzo A, et al. Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett 2007;17(17):4866-72
   PubMed Web of Science ®Google Scholar
• Aggarwal M, Kondeti B, McKenna R. Insights towards sulfonamide drug specificity in alpha-carbonic anhydrases. Bioorg Med Chem 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar